Addressing the significance of acting early in T1D care, a group of diabetes experts delve into the impact of delaying intervention during stage 2 of the condition.
Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits
A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Study: COVID-19 Pandemic Disruptions in Cancer Screening Show Uneven Recovery in 2023
Cervical cancer screening rates remained below prepandemic levels, while rates for breast and colorectal cancers rebounded from pandemic declines.
Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.
FDA Approves First Rapid-Acting Insulin Biosimilar for Diabetes: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Diabetes
Merilog joins two long-acting insulin biosimilar products approved in 2021, bringing the total to three insulin biosimilars available in the United States.